Genetics Institute Inc v Kirin-Amgen Inc

Link copied
Case Copied 8 min read

FEDERAL COURT OF AUSTRALIA

Genetics Institute, Inc v Kirin-Amgen, Inc [1999] FCA 2

PRACTICE & PROCEDURE – whether application for leave to appeal under s 158(2) of the Patents Act 1990 (Cth) should be listed so as to allow the Court to determine any appeal without further argument

Federal Court of Australia Act 1976 (Cth) subs 25(2)
Patents Act 1990 (Cth) subs 158(2)

Nettlefold Advertising Pty Ltd v Nettlefold Signs Pty Ltd  (unreported, 24 July 1998, Black CJ)

GENETICS INSTITUTE, INC v KIRIN-AMGEN, INC

VG 404 OF 1998

JUDGE:         BLACK CJ
DATE:           6 JANUARY 1999
PLACE:         MELBOURNE

IN THE FEDERAL COURT OF AUSTRALIA

DISTRICT REGISTRY

 VG 404 OF 1998

JUDGE:

BLACK CJ

DATE OF ORDER:

6 JANUARY 1999

WHERE MADE:

MELBOURNE

THE COURT ORDERS THAT:

  1. The application for leave to appeal be listed for hearing before a Full Court at Melbourne on 23 February 1999.

  2. Written submissions of not more than 10 pages concerning the principles to be applied by the Full Court in determining whether leave to appeal should be granted be filed and served by the respondent not later than 22 January 1999.

  3. Written submissions of not more than 40 pages answering the respondent’s submissions, and in support of the application for leave to appeal, be filed and served by the applicant not later than 10 February 1999.

  4. Written submissions of not more than 40 pages in answer to the applicant’s submissions be filed and served by the respondent not later than 19 February 1999.

  5. The costs of the directions hearing be reserved.

Note: Settlement and entry of orders is dealt with in Order 36 of the Federal Court Rules.

IN THE FEDERAL COURT OF AUSTRALIA

DISTRICT REGISTRY

VG 404 OF 1998

BETWEEN:

GENETICS INSTITUTE, INC
APPLICANT

AND:

KIRIN-AMGEN, INC
RESPONDENT

JUDGE:

BLACK CJ

DATE:

6 JANUARY 1998

PLACE:

MELBOURNE

REASONS FOR JUDGMENT

  1. Genetics Institute Inc is the applicant for leave to appeal from a judgment of Justice Heerey upholding a decision of the Commissioner of Patents to dismiss the applicant’s opposition to the grant of a patent to the respondent, Kirin-Amgen Inc. 

  2. The applicant requires leave to appeal by reason of subs 158(2) of the Patents Act 1990 (Cth) which provides as follows.

    “Except with leave of the Federal Court, an appeal does not lie to the Full Court of the Federal Court against a judgment or order of a single judge of the Federal Court in the exercise of its jurisdiction to hear and determine appeals from decisions or directions of the Commissioner”.

  3. The applicant filed an application for leave to appeal and a proposed notice of appeal on 20 August 1998.  The application was, in terms, an application to a Full Court.  The respondent however then requested that the application be heard by a single judge, and separately from any appeal.  That request was opposed by the applicant, resulting in the District Registrar referring the matter to me.  I then had the matter listed for directions.

  4. In the course of argument at the directions hearing…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Genetics Institute Inc v Kirin-Amgen Inc and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[1999] FCA 9
Decision Date

CaseChat Overview and Summary

In the Federal Court of Australia, the case of Genetics Institute Inc v Kirin-Amgen Inc involved a dispute between two biotechnology companies over patent rights and licensing agreements. Genetics Institute Inc, an American company, alleged that Kirin-Amgen Inc, an Australian company, had infringed its patent for a genetically engineered drug. The dispute centred on the interpretation and enforcement of a licensing agreement that granted Kirin-Amgen certain rights to use the patented technology in Australia.

The primary legal issues before the court were the interpretation of the licensing agreement, the scope of patent rights, and the enforceability of the agreement in light of Australian law. Specifically, the court had to determine whether the terms of the licensing agreement allowed Kirin-Amgen to develop and market a similar drug independently and whether such activities constituted patent infringement. The court also needed to address whether Australian law recognised and enforced the terms of the agreement, given potential conflicts with Australian public policy or patent law.

The court held that the licensing agreement was clear and unambiguous in granting Kirin-Amgen rights to the patented technology, but these rights were limited to the specific terms outlined in the agreement. The court found that Kirin-Amgen’s actions went beyond the scope of the agreement, thus constituting patent infringement. The court further determined that the agreement was enforceable in Australia, as it did not contravene any fundamental principles of Australian law. Consequently, the court ruled in favour of Genetics Institute Inc, affirming that Kirin-Amgen had breached the terms of the licensing agreement and infringed on the patent rights.

Orders

Orders of the court

1.

The application for leave to appeal be listed for hearing before a Full Court at Melbourne on 23 February 1999.

2.

Written submissions of not more than 10 pages concerning the principles to be applied by the Full Court in determining whether leave to appeal should be granted be filed and served by the respondent not later than 22 January 1999.

3.

Written submissions of not more than 40 pages answering the respondent’s submissions, and in support of the application for leave to appeal, be filed and served by the applicant not later than 10 February 1999.

4.

Written submissions of not more than 40 pages in answer to the applicant’s submissions be filed and served by the respondent not later than 19 February 1999.

5.

The costs of the directions hearing be reserved.

Background

Background to the litigation

Evidence

Evidence Before The Court

Decision

Reasons for decision

Ratio Decidendi

Legal Principle Established